Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Should You Buy?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped up prior to trading on Thursday. The stock had previously closed at $16.60, but opened at $17.30. Daiichi Sankyo shares last traded at $16.93, with a volume of 75,355 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DSNKY. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Monday, September 21st. Two equities research analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Daiichi Sankyo Price Performance

The company has a 50 day moving average of $17.80 and a 200 day moving average of $17.18. The stock has a market capitalization of $31.54 billion, a price-to-earnings ratio of 19.69, a price-to-earnings-growth ratio of 1.77 and a beta of -0.11. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, equities research analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Its business is centered on oncology, with additional operations in areas such as cardiovascular disease, immunology, and other serious medical conditions.

The company’s oncology portfolio includes antibody-drug conjugates, a technology designed to deliver potent cancer treatments more selectively to tumor cells. Daiichi Sankyo develops and commercializes medicines independently and through collaborations, including its partnership with AstraZeneca on trastuzumab deruxtecan, marketed as Enhertu, for certain cancer indications.

Daiichi Sankyo was formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo.